Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents) No other concurrent investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study Concurrent use of other investigational agents Patients may not be receiving any other concurrent investigational agents, or have received any investigational agent within four weeks of commencing this protocol. Concurrent therapy with any other investigational drug Patients may not receive any concurrent investigational agents while on study Concurrent use of any other investigational agents Patients who are receiving concurrent investigational therapy; Concurrent administration of any other investigational agents Subject receiving concurrent chemotherapeutics or investigational agents within days of study entry, including gliadel wafers or gliasite application. Concurrent administration of other cancer specific therapy or investigational agents during the course of this study is not allowed Concurrent treatment with any other investigational therapeutic agents No other concurrent chemotherapeutic or investigational agents for this cancer. However, concurrent glucocorticoids are allowed; Receiving concurrent investigational therapy No other concurrent investigational agents are allowed Concurrent use of other investigational agents Patients receiving concurrent investigational chemotherapeutic agents Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents). Patients receiving any concurrent investigational agents Concurrent use of restricted agents Concurrent enrollment on another investigational therapy Concurrent use of other investigational agents or Optune device Concurrent use of investigational therapeutic agent Concurrent use of any other investigational agents Concurrent use of investigational therapeutic agent Subjects may not be receiving any other investigational agents; concurrent enrollment in another clinical investigational drug or device study is prohibited Concurrent use of any other investigational agents The use of other concurrent investigational agents will not be allowed Concurrent use of other investigational agents Concurrent use of any other investigational agents Patients receiving any other investigational agents, or concurrent chemotherapy, radiation therapy, or immunotherapy Concurrent administration of any other investigational agents Patients who are receiving any other concurrent investigational agents (patients are eligible to enroll weeks after completion of prior agent) Concurrent treatment with other investigational agents is not permitted Concurrent therapy with any other investigational drug Concurrent use of other investigational agents. Concurrent treatment with other investigational drugs. Patients may not receive any other concurrent investigational agents while on study Concurrent treatment with other investigational agents Concurrent anti-cancer treatment in another investigational trial Concurrent use of investigational therapeutic agent Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents) other than temozolomide Concurrent use of any other investigational agents. Use of investigational agents or concurrent anti-cancer treatment within the last weeks of registration Other concurrent investigational agents; Concurrent therapy with other investigational agents Concurrent anti-cancer treatment in another investigational trial Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents) Concurrent use of other investigational agents Concurrent therapy with any other investigational agent ANY concurrent investigational agents No concurrent methotrexate, thiotepa, cytarabine, or investigational agents Concurrent use of other investigational agents and patients who have received investigational drugs =< weeks prior to enrollment Concurrent treatment with other investigational agents(s) No other concurrent investigational treatment Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents, radiation or immunotherapy) within weeks of the first dose of the study drug Concurrent use of any other investigational agents on a clinical trial No other concurrent investigational agents Patients who are receiving any other investigational agents with the intent to treat myeloma; permitted concurrent therapies include:\r\n* Bisphosphonates Concurrent use of other investigational agent Patient is receiving concurrent treatment with other investigational agents not allowed as part of the combination regimen in the parental study protocol. Concurrent enrollment in another investigational clinical study Patients receiving concurrent investigational drugs Concurrent investigational drugs Concurrent use of investigational agents Concurrent use of investigational therapeutic agent Concurrent use of investigational therapeutic agent Concurrent therapy with an investigational agent Concurrent therapy with investigational agents Concurrent systemic therapy for prostate cancer with investigational agents.